Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing <i>Corynebacterium glutamicum</i> as a surrogate of <i>Mycobacterium tuberculosis</i> for DNA gyrase inhibitor design.

bioRxiv : the preprint server for biology·2026
Same author

Direct carbapenemase typing from disc diffusion antibiograms with MALCA (MAchine Learning CArbapenemase).

Nature communications·2026
Same author

Alpibectir-Ethionamide combination (AlpE) for the treatment of tuberculosis.

Nature communications·2026
Same author

Occupational Transmission of Extensively Drug-Resistant Tuberculosis, France.

Emerging infectious diseases·2026
Same author

Evaluation of the BL-RED test and comparison with the β-LACTA test for rapid detection of resistance to third-generation cephalosporins in <i>Enterobacterales</i> on early culture of positive blood cultures.

Microbiology spectrum·2026
Same author

Diagnostic algorithms for tuberculosis in Europe: insights from the European Reference Laboratory Network for Tuberculosis (ERLTB-Net).

The Lancet regional health. Europe·2025

Related Experiment Video

Updated: Jul 19, 2026

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

[Trends in tuberculosis treatment duration].

Nicolas Veziris1, Alexandra Aubry2, Chantal Truffot-Pernot2

  • 1Service de pneumologie,; Laboratoire de bactériologie, Groupe hospitalier Pitié-Salpêtrière, Assistance publique Hôpitaux de Paris, Centre national de référence de la résistance des mycobactéries aux antituberculeux, Faculté de médecine Pierre et Marie Curie, Université Paris 6, Paris (75).

Presse Medicale (Paris, France : 1983)
|November 7, 2006
PubMed
Summary

Tuberculosis treatment requires multiple antibiotics for extended periods to combat dormant bacteria. New drugs promise shorter treatment durations for all forms of tuberculosis.

Related Experiment Videos

Last Updated: Jul 19, 2026

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Tuberculosis (TB) treatment is characterized by long durations and multidrug therapy.
  • Multidrug therapy prevents the emergence of resistant tuberculosis strains.
  • Dormant bacilli, difficult to eradicate, necessitate prolonged treatment regimens.

Purpose of the Study:

  • To review the key characteristics of tuberculosis treatment.
  • To highlight the role of specific drugs in reducing treatment duration.
  • To discuss the impact of drug resistance and new drug development on TB therapy.

Main Methods:

  • Literature review of tuberculosis treatment strategies.
  • Analysis of the impact of rifampin and pyrazinamide on treatment length.
  • Examination of challenges posed by drug-resistant tuberculosis.

Main Results:

  • Rifampin and pyrazinamide are crucial for targeting dormant bacilli.
  • Rifampin reduced TB treatment duration from 18 to 9 months; pyrazinamide further reduced it to 6 months.
  • Treatment duration increases significantly with drug resistance, reaching 18-24 months in severe cases.

Conclusions:

  • Effective TB treatment relies on combination therapy and potent drugs like rifampin and pyrazinamide.
  • Drug resistance and toxicity necessitate longer treatment or alternative regimens.
  • Emerging antituberculosis drugs offer potential for shorter treatment durations for all TB types.